Latest Chronic myelogenous leukemia Stories
High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2,
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.
Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/
FLINT, Mich., May 23, 2014 /PRNewswire-iReach/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will be distributing SYNRIBO(®) (omacetaxine mepesuccinate),
The Leukemia & Lymphoma Society and Oregon Health & Sciences University forged Beat AML collaboration to find effective therapies for acute myeloid leukemia patients WHITE PLAINS,
CML-IQ delivers timely, accurate information to help people make informed decisions. Montreal, QC (PRWEB) April 29, 2014 Every day in North America,
- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb.
The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.